ClinicalTrials.gg

Program

RET Inhibitor HS-10365

Also written as “HS-10365” and “HS-10365 capsules”.

In Hansoh Pharmaceutical Group’s pipeline, RET. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Hansoh Pharmaceutical Group.

Furthest: phase 2, since Jan 9, 20223 company-led studies, 3 open or runningNext primary completion: Aug 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group33 open or runningphase 2since Jan 9, 2022Jan 9, 2022Aug 31, 2027phase 2 · NCT06147570
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-10365 (RET), phase 4, as of Aug 26, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2022First study: phase 2 study in Solid TumorFirst studyNCT05207787 · 306 planned · China
  2. Nov 17, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06147570 · 62 planned · China
  3. Dec 23, 2024Phase 1 study in Carcinoma, Non-Small-Cell LungNCT06823258 · 32 planned

Ahead

  1. Aug 31, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06147570

TargetBeta

“RET”the company's pipeline, read by Claude · source
“An orally bioavailable selective inhibitor of the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), ”NCIt, by rule

Other programs on RET

ProgramCompanyFurthest phaseStudies
regorafenibruleBayerphase 440
selpercatinibruleEli Lillyphase 419
pralsetinibruleHoffmann-La Rochephase 47
quizartinibruleDaiichi Sankyophase 322
TRK/RET Inhibitor ND-003ruleshenzhen-newdel-biotech-co-ltdphase 23
RET Inhibitor FHND5071Sino Biopharmaceuticalphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06823258Carcinoma, Non-Small-Cell Lung1Not yet recruitingJul 31, 202532
NCT06147570Carcinoma, Non-Small-Cell Lung · China2RecruitingAug 31, 202762
NCT05207787Solid Tumor · China2RecruitingApr 30, 2024306

How it is read

Names in the registry

  • “HS-10365”, 2 entries
  • “HS-10365 capsules”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.